Share This Article:

Community Pharmacy Prescription Screening in the UAE

Abstract Full-Text HTML XML Download Download as PDF (Size:148KB) PP. 83-91
DOI: 10.4236/pp.2014.51013    2,987 Downloads   4,783 Views   Citations
Author(s)    Leave a comment

ABSTRACT

This study was designed to investigate and to evaluate pharmacists in the United Arab Emirates-Fujairah-Dibba-Sharjah-Abu Dhabi. The study is concerned with how pharmacists deal with prescriptions (OTC-Ethical) and their behavior with their patients in comparison to standards. Objectives: The study’s objective is to evaluate current pharmacists, who deal with a large number of patients and affect their lives. Methodology: A descriptive and comparative prospective prescription screening study, which evaluates data in OTC and ethical prescriptions.1000 prescriptions (including OTC and ethical) were collected randomly from community and hospital pharmacies (Fujairah, Dibba, Sharjah and Abu-Dhabi) in the United Arab Emirates. Data collection was carried out within a 3-month time period. SPSS (version 16) was used for data entry and analysis in which each prescription was evaluated using certain parameters. Results: One thousand prescriptions were collected, of which 10.6% were OTC and 89.4% were ethical, which were included in the analysis. Analysis was carried out to obtain percentages, frequencies and general cross tabs. Conclusion: Our study showed that most patients received no oral or written information about how to use the medication, how to manage adverse effects, what precautions to take, or what to do in case of an overdose. Also, some patients were not asked basic questions by the pharmacist that were needed to assess them, which is very far from the concept of pharmaceutical care delivered all over the world.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

M. Alomar, "Community Pharmacy Prescription Screening in the UAE," Pharmacology & Pharmacy, Vol. 5 No. 1, 2014, pp. 83-91. doi: 10.4236/pp.2014.51013.

References

[1] M. Everard, M. Lesko and C. Wiback, “New Tool to Enhance Role of Pharmacists in Health Care,” WHO, 2006.
http://www.who.int/mediacentre/news/new/2006/nw05/en/
[2] H. M. Belknap and S. A. Lanzotti, “Application of Software Design Principles and Debugging Methods to an Analgesia Prescription Reduces Risk of Severe Injury from Medical Use of Opioids,” Clinical Pharmacology & Therapeutics, Vol. 84, No. 3, 2008, pp. 385-392.
http://www.ncbi.nlm.nih.gov/pubmed/18388884
[3] J. Netzer and K. C. Clauson, “Comparison of State Requirements for Preprinted Prescriptions,” American Journal of Health-System Pharmacy, Vol. 26, No. 21, 2005, pp. 2278-2282.
http://www.medscape.com/viewarticle/515546_1
[4] M. F. Zwarenstein, K. N. Dainty and S. Quan, “A Cluster Randomized Trial Evaluating Electronic Prescribing in an Ambulatory Care Setting,” Trials, Vol. 3, No. 8, 2007, p. 28.
http://www.ncbi.nlm.nih.gov/pubmed/17915028
[5] A. R. Kuyper, “Patient Counseling Detects Prescription Errors,” Hospital Pharmacy, Vol. 28, No. 12, 1993, pp. 1180-1184.
http://www.ncbi.nlm.nih.gov/pubmed/10130615
[6] F. A. Elizabeth, K. N. Barker and B. J. Carnahan, “National Observational Study of Prescription Dispensing Accuracy and Safety in 50,” Journal of American Pharmacists Association, Vol. 43, No. 2, 2003, pp. 191-200.
http://www.medscape.com/viewarticle/451962_print
[7] R. G. Neville, F. Robertson, S. Livingstone and I. K. Crombie, “A Classification of Prescription Errors,” Journal of the Royal College of General Practitioners, Vol. 39, No. 320, 1989, pp. 110-112.
http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=1711802&pageindex=1
[8] P. J. Barry, P. Gallagher, C. Ryan and D. O’mahony, “START (Screening Tool to Alert Doctors to the Right Treatment)—An Evidence-Based Screening Tool to Detect Prescribing Omissions in Elderly Patients,” Age Ageing, Vol. 36, No. 6, 2007, pp. 632-638.
http://ageing.oxfordjournals.org/cgi/content/abstract/afm118v1
[9] B. Dean, M. Schachter and C. Vincent, “Prescribing Errors in Hospital Inpatients: Their Incidence and Clinical Significance,” Quality & Safety in Health Care, Vol. 11, 2002, pp. 340-344.
http://qshc.bmj.com/cgi/content/abstract/11/4/340
http://dx.doi.org/10.1136/qhc.11.4.340
[10] M. G. Abdullah and N. Barber, “Systematic Review of Medication Errors in Pediatric Patients,” Annals of Pharmacotherapy, Vol. 40, No. 10, 2006, pp. 1766-1776.
http://www.medscape.com/viewarticle/549356
[11] P. P. Dobesh, “Managing Hypertension in Patients with Type 2 Diabetes Mellitus,” American Journal of HealthSystem Pharmacy, Vol. 63, No. 12, 2006, pp. 1140-1149.
http://www.medscape.com/viewarticle/535775
[12] B. Berenguer, C. La Casa, M. J. de la Matta and M. J. Calero, “Pharmaceutical Care: Past, Present and Future,” Current Pharmaceutical Design, Vol. 10, No. 31, 2004, pp. 3931-3946.
http://www.ingentaconnect.com/content/ben/cpd/2004/00000010/00000031/art00009
[13] B. Henk, A. G. M. Peter, D. Leufkens, G. M. Hubert and E. C. G. Antoine, “Evaluation of the Clinical Value of Pharmacists’ Modifications of Prescription Errors,” British Journal of Clinical Pharmacology, Vol. 58, No. 5, 2004, pp. 503-511.
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1884615
[14] C. J. Hawkey, S. Hodgson, A. Norman and T. K. Daneshmend, “Effect of Reactive Pharmacy Intervention on Quality of Hospital Prescribing,” BMJ, Vol. 300, 1990, pp. 986-990.
http://www.bmj.com/cgi/content/abstract/300/6730/986
http://dx.doi.org/10.1136/bmj.300.6730.986
[15] J. Y. Wick and G. R. Zanni, “Informed Consent: What Every Pharmacist Should Know,” Journal of American Pharmacists Association, Vol. 41, No. 4, 2001.
http://www.medscape.com/viewarticle/406721
[16] M. R. Amsler, “Pharmaceutical Care in Chain Pharmacies: Beliefs and Attitudes of Pharmacists and Patients,” Journal of American Pharmacists Association, Vol. 41, No. 6, 2002, pp. 850-855.
[17] W. Hammond, “Collaborative Drug Therapy Management by Pharmacists,” Pharmacotherapy, Vol. 23, No. 9, 2003, pp. 1210-1225.
http://www.medscape.com/viewarticle/461410
http://dx.doi.org/10.1592/phco.23.1.9.31916
[18] W. R. Vincent, K. M. Smith and D. Steinke, “Opportunities for Pharmacists in Public Health,” American Journal of Health-System Pharmacy, Vol. 64, No. 19, 2007, pp. 2002-2007.
[19] S. S. Sen and J. Thomas III, “Assessment of a PatientBased Pharmaceutical Care Scale,” American Journal of Health-System Pharmacy, Vol. 57, No. 17, 2000.
http://www.medscape.com/viewarticle/406909
[20] W. Nilaward, H. L. Mason and G. D. Newton, “Community Pharmacist-Child Medication Communication: Magnitude, Influences and Content,” Journal of American Pharmacists Association, Vol. 45, 2005, pp. 354-362.
http://dx.doi.org/10.1331/1544345054003778
[21] S. Kripalani, V. Vigil and K. R. Epstein, “Frequency and Predictors of Prescription-Related Issues after Hospital Discharge,” Journal of Hospital Medicine, Vol. 3, No. 1, 2008, pp. 12-19.
http://www.medscape.com/viewarticle/573055_4
[22] J. T. Lurk, “Effects of Changes in Patient Cost Sharing and Drug Sample Policies on Prescription Drug Costs and Utilization in a Safety-Net-Provider Setting,” American Journal of Health-System Pharmacy, Vol. 61, No. 3, 2004, pp. 267-272.
http://www.medscape.com/viewarticle/468784_2
[23] C. W. Cranor and D. B. Christensen, “The Asheville Project: Short-Term Outcomes of a Community Pharmacy Diabetes Care Program,” Journal of the American Pharmaceutical Association, Vol. 43, No. 2, 2003, pp. 149-159.
http://www.ncbi.nlm.nih.gov/pubmed?term=12688433
[24] S. M. Gaffney, “Key Articles and Guidelines in the Management of Hypertension,” Pharmacotherapy, Vol. 28, No. 8, 2008, pp. 1041-1058.
http://www.medscape.com/viewarticle/578718
[25] P. A. Howard, “Drug Therapy Recommendations from the 2005 ACC/AHA Guidelines for Treatment of Chronic Heart Failure,” The Annals of Pharmacotherapy, Vol. 40, No. 9, 2006, pp. 1607-1617.
[26] A. Marja, A. Riitta and E. Hannes, “The ‘Questions to Ask about Your Medicines’ Campaign: An Evaluation of Pharmacists and the Public’s Response,” Medical Care, Vol. 36, No. 3, 1998, pp. 422-427.
[27] O. E. Boris and Anthonius, “Effectiveness of Interventions by Community Pharmacists to Improve Patient Adherence to Chronic Medication; a Systemic Review,” The annals of Pharmacotherapy, Vol. 39, 2005, p. 324.
[28] K. Beaucage, “Telephone Follow-Up of Patients Receiving Antibiotic Prescriptions from Community Pharmacies,” American Journal of Health-System Pharmacy, Vol. 63, No. 6, 2006, pp. 557-563.
http://www.medscape.com/viewarticle/527440_4
[29] R. L. Brown, “Pharmacoepidemiology of Potential Alcohol-Prescription Drug Interactions among Primary Care Patients with Alcohol-use Disorders,” Journal of the American Pharmacists Association, Vol. 47, No. 2, 2007, pp. 135-139.
http://www.medscape.com/viewarticle/557157
[30] L. Richwine, “U.S. FDA Proposes New Pregnancy Labels for Medicines,” Reuters Health Information, 2008.
http://www.reuters.com/article/2008/05/28/us-drugs-pregnancy-idUSN2844317120080528
[31] L. A. Dent, J. G. Scott and E. Lewis, “Pharmacists-Managed Tobacco Cessation Program in Veterans Health Administration Community Based Outpatient Clinic,” Journal of the American Pharmacists Association, Vol. 44, No. 6, 2005, pp. 700-715.
http://www.medscape.com/viewarticle/498148
[32] J. Y. F. Wu, W. Y. S. Leung, S. Chang, B. Lee, P. C. Y. Tong and J. C. N. Chan, “Effectiveness of Telephone Counseling by a Pharmacist in Reducing Mortality in Patients Receiving Polypharmacy: Randomized Controlled Trial,” BMJ, Vol. 333, 2006, p. 522.
http://www.bmj.com/cgi/content/abstract/333/7567/522?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=telephone&search
id=1&FIRSTINDEX=0&volume=333&issue=7567&resourcetype=HWCIT
http://dx.doi.org/10.1136/bmj.38905.447118.2F

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.